慢粒急变白血病CCLG-08方案治疗的效果评价  

The Effect Evaluation of CCLG-08 for CML Leukemia of Acute Stage

作　　者：谷月丽[1] 

机构地区：[1]商丘市第一人民医院血液内科,河南商丘476100

出　　处：《中国医药指南》2016年第10期31-31,33,共2页Guide of China Medicine

摘　　要：目的寻找一种更好的针对慢粒急变白血病的治疗方案。方法选取2010年1月1日至2015年1月1日我院收住的慢粒急变白血病86例患者作为研究对象,并随机分为观察组(43例)和对照组(43例),观察组患者采取CCLG-08治疗方案,而对照组患者采用CAMS-ALL-2002治疗方案,而后对两组患者进行疗程后效果评价,评价指标包括:临床症状改善情况、并发症发生率及感染部位确定率。结果观察组临床改善效果、感染部位确定率均优于对照组。结论 CCLG-08方案治疗慢粒急变白血病能较好的改善患者的临床症状及提高感染并发症确诊率,值得临床推广应用。Objective To looking for a better treatment program for CML leukemia of acute stage. Methods Select 86 cases of CML leukemia patients of acute stage from January 2010 to January 2015, who were randomly divided into observation group （43 cases）and control group （43 cases）, the patients of observation group were treated by CCLG-08 scheme, and the patients of control group were treated by CAMS-ALL-2002 treatment, then compared the two groups with each other after treatment cycle. The evaluation indicators include： the improvement of clinical symptoms and the complication rate and the determine rate of infection the comparison of two groups of patients with leukemia clinical symptoms improved the effect and complications rate and the infection distribution of cases cart be confirmed. Results The evaluation indicators of the observation group are better than control group. Conclusions CCLG-08 treatment is a better plan for CML leukemia of acute stage, it is worthy of clinical application.

关 键 词：慢粒急变白血病 CCLG-08 疗效评价 

分 类 号：R733.7[医药卫生—肿瘤]